Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease
Authors:
Open Access
- 20 February 2025
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-11
Abstract
Aim: The aim of our multicenter study was to investigate the safety and efficacy of enzyme replacement therapy (ERT) and chaperone therapy on the disease progression in female Fabry disease (FD) patients and to compare the individual treatment regimens. Methods: Data from 3 consecutive visits of 102 female FD patients from 6 Fabry centers were retrospectively analyzed. According to their FD-specific treatment, patients were separated in 5 groups: Newly agalsidase-beta- [n = 18], agalsidase-alfa- [n = 29] and migalastat-[n = 14] treated patients, and long-term agalsidase-beta- [n = 7] and agalsidase-alfa-[n = 34] treated patients. Clinical presentation and laboratory data, including plasma lyso-Gb3 levels were assessed. Results: Treatment with agalsidase-beta, agalsidase-alfa, and migalastat was safe and severe adverse events were rare. Newly and long-term-treated patients presented a stable disease course over time. None of the patients required hospitalization due to cardiac events. Overall septum thickness remained stable in all groups (p > 0.05). Estimated glomerular filtration rate (eGFR) only slightly decreased in patients treated with agalsidase-alfa [newly- and long-term-treated: -1.5 ± 3.2 and − 1.3 ± 3.9 ml/min/1.73 m²/year; p = 0.0056 and p = 0.0187, respectively] but the decrease was in the range of natural eGFR decline. eGFRs in agalsidase-beta and migalastat-treated patients were stable. No clinically relevant differences concerning treatment efficacy between agalasidase-beta, agalsidase-alfa, and migalastat were detected. Conclusion: We conclude that treatment of females with agalsidase-beta, agalsidase-alfa, and migalastat was safe. Independent of the chosen treatment regimen, nearly all patients presented with a stable disease course over time. In our cohort, a comparison of therapy efficacies showed no relevant clinical differences between the groups.Keywords
Funding Information
- Universitätsklinikum Münster
This publication has 29 references indexed in Scilit:
- Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyMolecular Genetics and Metabolism, 2022
- Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry RegistryMolecular Genetics and Metabolism, 2022
- A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry diseaseKidney International, 2022
- Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT studyMolecular Genetics and Metabolism, 2020
- An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry DiseaseEuropean Journal of Heart Failure, 2020
- The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of expertsMolecular Genetics and Metabolism, 2019
- Fabry disease revisited: Management and treatment recommendations for adult patientsMolecular Genetics and Metabolism, 2018
- Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblastsMolecular Genetics and Metabolism, 2015
- A validated disease severity scoring system for Fabry diseaseMolecular Genetics and Metabolism, 2010
- Fabry's diseaseThe Lancet, 2008